Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc's. (“HTG”) mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary target protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG Edge chemistry and automation with NGS technology. The HTG EdgeSeq system enables fast and easy use of NGS instruments for molecular profiling.

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
TUCSON, Ariz. , May 03, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors (“Board”).
Toggle Summary Dr. Ann Hanham Joins HTG Molecular Diagnostics’ Board of Directors
TUCSON, Ariz. , Aug. 29, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Ann F. Hanham , Ph.D. has been appointed to its Board of Directors (“Board”).
Toggle Summary HTG and MD Anderson Cancer Center Enter Into a Sponsored Research Agreement to Investigate New Molecular Diagnostics for Lung Cancer Using HTG's Next-Generation Sequencing Solution for Gene Expression
TUCSON, Ariz. , June 1, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications and The University of Texas MD Anderson Cancer Center have entered into a 2-year Sponsored Research Agreement to support
Toggle Summary HTG Announces Completion of IVD Development and Supply Agreement With Illumina
Thursday, October 30, 2014 - 08:08 HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ:ILMN), under which HTG will have the right to develop
Toggle Summary HTG Announces Issuance of Two Method Patents Related to its Technology
TUCSON, Ariz. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the United States Patent and Trademark Office has issued two U.S.

Stock Chart

SEC Filings

Filing date Description

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3